Date: 2014-09-11
Type of information: Pipeline acquisition
Acquired company: GE Healthcare’s FDG-PET Radiopharmaceutical Business in Italy
Acquiring company: Advanced Accelerator Applications (France)
Amount: undisclosed
Terms: * On September 11, 2014, Advanced Accelerator Applications (AAA), an international specialist in Molecular Nuclear Medicine (MNM) announced that it has entered into an agreement with GE Healthcare in Italy to acquire its Italian FDG-PET imaging agent business (fluorodeoxyglucose photon emission tomography). This acquisition includes the licence to market GE Healthcare’s SteriPET®(FDG) imaging agent in Italy. With this acquisition AAA reinforces its position as one of the leading companies in the PET market in Italy.
Details: Advanced Accelerator Applications is a radiopharmaceutical company founded in 2002 to develop innovative diagnostic and therapeutic products. AAA’s main focus is in the field of Molecular Imaging and targeted, individualized therapy for the management of patients with serious conditions (“Personalized Medicine”). AAA has a portfolio of six diagnostic PET and SPECT products and several diagnostic and therapeutic product candidates including flagship product candidate Lu-DOTATATE, currently in a pivotal Phase III clinical trial for the treatment of GEP-NETs (gastroenteropancreatic neuroendocrine tumors) in 51 clinical centers in the United States and Europe.
AAA’s leading diagnostic PET product is Gluscan®, its branded fluorodeoxyglucose (FDG) PET imaging agent. Gluscan® assists in the diagnosis of serious diseases, primarily in oncology, by assessing glucose metabolism. AAA currently has 13 PET production facilities based in France, Germany, Italy, Poland, Portugal and Spain. In 2013 AAA reported sales of €53.8 million (+31.77% vs. 2012).
Related: Molecular nuclear medicine Radiopharmaceuticals
